Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.

British Journal of Haematology
Maria L MoletiRobin Foà

Abstract

Aggressive B-cell non-Hodgkin lymphoma (B-NHL) accounts for ≈60% of NHL in children/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large B-cell lymphoma, short intensive multiagent chemotherapy is associated with a five-year event-free survival of around 90%. Very few children/adolescents with aggressive B-NHL show a relapsed/refractory (r/r) disease. The outcome is poor, with cure rates <30%, and there is no standard of care. Rituximab-containing salvage regimens may provide a complete/partial response in 60-70% of cases. However, long-term survival is <10% for non-transplanted patients. Autologous or allogeneic haematopoietic stem cell transplant is, nowadays, the best option for responding patients, with survival rates around 50%. The benefit of autologous versus allogeneic HSCT is not clear. Numerous novel therapies for r/r B-NHL are currently being tested in adults, including next-generation monoclonal antibodies, novel cellular therapy strategies and therapies directed against new targets. Some are under investigation also in children/adolescents, with promising preliminary results.

References

Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C GentetC Raybaud
Jan 1, 1995·American Journal of Nephrology·E C ClarkM G Rinaldi
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P BowmanS Murphy
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LazzarinoP Möller
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K SeidemannUNKNOWN NHL Berlin-Frankfurt-Münster Group
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erin Cooney-QualterUNKNOWN Children's Oncology Group
Dec 18, 2008·British Journal of Haematology·Jessica HochbergMitchell S Cairo
Oct 6, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Thomas G GrossMary Eapen
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anjali AdvaniLuis Fayad
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea MeinhardtUNKNOWN Berlin-Frankfurt-Münster group
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard E HarrisMitchell S Cairo
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Feb 8, 2011·Pediatric Blood & Cancer·Maria Luisa MoletiAnna Maria Testi
Jan 13, 2012·Blood·Wolfram KlapperUNKNOWN Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe
Nov 15, 2012·Blood·Mary GerrardUNKNOWN French-American-British/Lymphome Malins de Burkitt 96 (FAB/LMB 96) International Study Committee
Apr 12, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Jul 19, 2013·The New England Journal of Medicine·Wyndham H WilsonKieron Dunleavy
Jul 19, 2013·The New England Journal of Medicine·Amanda F CashenNancy L Bartlett
Jul 22, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hyery KimHyeo Seop Ahn
Nov 2, 2014·Blood·Dieter HoelzerUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Dec 3, 2014·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Yao WangWei-dong Han
May 27, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenEric Jacobsen
Jul 21, 2015·Nature Medicine·Wyndham H WilsonLouis M Staudt
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique Minard-ColinCatherine Patte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.